Literature DB >> 26672497

Race and colorectal cancer screening compliance among persons with a family history of cancer.

Adeyinka O Laiyemo1, Nicole Thompson1, Carla D Williams1, Kolapo A Idowu1, Kathy Bull-Henry1, Zaki A Sherif1, Edward L Lee1, Hassan Brim1, Hassan Ashktorab1, Elizabeth A Platz1, Duane T Smoot1.   

Abstract

AIM: To determine compliance to colorectal cancer (CRC) screening guidelines among persons with a family history of any type of cancer and investigate racial differences in screening compliance.
METHODS: We used the 2007 Health Information National Trends Survey and identified 1094 (27.4%) respondents (weighted population size = 21959672) without a family history of cancer and 3138 (72.6%) respondents (weighted population size = 58201479) with a family history of cancer who were 50 years and older. We defined compliance with CRC screening as the use of fecal occult blood testing within 1 year, sigmoidoscopy within 5 years, or colonoscopy within 10 years. We compared compliance with CRC screening among those with and without a family member with a history of cancer.
RESULTS: Overall, those with a family member with cancer were more likely to be compliant with CRC screening (64.9% vs 55.1%; OR = 1.45; 95%CI: 1.20-1.74). The absolute increase in screening rates associated with family history of cancer was 8.2% among whites. Hispanics had lowest screening rates among those without family history of cancer 41.9% but had highest absolute increase (14.7%) in CRC screening rate when they have a family member with cancer. Blacks had the lowest absolute increase in CRC screening (5.3%) when a family member has a known history of cancer. However, the noted increase in screening rates among blacks and Hispanics when they have a family member with cancer were not higher than whites without a family history of cancer: (54.5% vs 58.7%; OR = 1.16; 95%CI: 0.72-1.88) for blacks and (56.7% vs 58.7%; OR = 1.25; 95%CI: 0.72-2.18) for Hispanics.
CONCLUSION: While adults with a family history of any cancer were more likely to be compliant with CRC screening guidelines irrespective of race/ethnicity, blacks and Hispanics with a family history of cancer were less likely to be compliant than whites without a family history. Increased burden from CRC among blacks may be related to poor uptake of screening among high-risk groups.

Entities:  

Keywords:  Colon cancer; Colonoscopy; Fecal blood test; Health disparities; Screening

Year:  2015        PMID: 26672497      PMCID: PMC4673393          DOI: 10.4253/wjge.v7.i18.1300

Source DB:  PubMed          Journal:  World J Gastrointest Endosc


  18 in total

1.  In search of a perfect solution to ensure that "no colon is left behind".

Authors:  Adeyinka O Laiyemo
Journal:  Dig Dis Sci       Date:  2011-12-20       Impact factor: 3.199

2.  Self reported attitude and behavior of young diabetics about discussing their disease.

Authors:  S Miglani; A Sood; P Shah
Journal:  Diabetes Res Clin Pract       Date:  2000-04       Impact factor: 5.602

3.  Racial and gender disparities in hereditary colorectal cancer risk assessment: the role of family history.

Authors:  Sonia S Kupfer; Sarah McCaffrey; Karen E Kim
Journal:  J Cancer Educ       Date:  2006       Impact factor: 2.037

4.  The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer.

Authors:  Harminder Singh; Zoann Nugent; Alain A Demers; Erich V Kliewer; Salaheddin M Mahmud; Charles N Bernstein
Journal:  Gastroenterology       Date:  2010-06-20       Impact factor: 22.682

5.  Perceived cancer risk: why is it lower among nonwhites than whites?

Authors:  Heather Orom; Marc T Kiviniemi; Willie Underwood; Levi Ross; Vickie L Shavers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02-16       Impact factor: 4.254

6.  Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Paul F Pinsky; Barnett S Kramer; Douglas Reding; Saundra Buys
Journal:  Am J Epidemiol       Date:  2003-05-01       Impact factor: 4.897

7.  Fatalism among elderly African Americans. Effects on colorectal cancer screening.

Authors:  B D Powe
Journal:  Cancer Nurs       Date:  1995-10       Impact factor: 2.592

8.  Negotiating cultures: disclosure of HIV-positive status among people from minority ethnic communities in Sydney.

Authors:  Henrike Körner
Journal:  Cult Health Sex       Date:  2007 Mar-Apr

9.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

Authors:  Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer
Journal:  CA Cancer J Clin       Date:  2008-03-05       Impact factor: 508.702

Review 10.  Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Authors:  H F A Vasen
Journal:  Aliment Pharmacol Ther       Date:  2007-12       Impact factor: 8.171

View more
  3 in total

1.  Persisting Racial Disparities in Colonoscopy Screening of Persons with a Family History of Colorectal Cancer.

Authors:  Meng-Han Tsai; Sudha Xirasagar; Piet C de Groen
Journal:  J Racial Ethn Health Disparities       Date:  2017-08-15

2.  Using self-reported data on the social determinants of health in primary care to identify cancer screening disparities: opportunities and challenges.

Authors:  A K Lofters; A Schuler; M Slater; N N Baxter; N Persaud; A D Pinto; E Kucharski; S Davie; R Nisenbaum; T Kiran
Journal:  BMC Fam Pract       Date:  2017-02-28       Impact factor: 2.497

3.  Racial/Ethnic Disparities on the Risk of Second Malignant Neoplasm Among Hodgkin Lymphoma Survivors.

Authors:  Han Xiao; Jianghua He; Simin Liang; Duo Cai; Qiao Zhou; Lanxiang Liu; Xinyu Yan; Jianxiang Chi; Qing Xiao; Li Wang
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.